Bristol Myers plans to double experimental treatments to expand research pipeline

Bristol Myers Squibb said on Thursday it plans to double the number of treatments it is testing in clinical trials, with a focus on cell therapies, over the next 18 months, as it contends with increasing generic competition for two of its top-selling drugs.